McKesson Corporation has reported strong third quarter results for fiscal 2025, raising its full year adjusted EPS guidance. Its earnings call saw considerable revenue growth and strategic advances, though the company did miss Q4 sales targets. The firm's share of the stock market continues to be turbulent. A big issue was the recent revision to a positive outlook, and a 'BBB+' rating affirmed by S&P Global. In a key development,
McKesson agreed to acquire an 80% stake in
PRISM Vision Holdings for $850 million, strengthening its specialty leadership. This move has sparked debate about its impact on the stock's price. The corporation had a Q3 '25 revenue of $95.3 billion, with an adjusted EPS of $8.03 surpassing estimates. However, its share fell following Q3 results that missed estimates, despite raising guidance. As a long-term investment,
McKesson shows promise with projections of a $32.55-$32.95 adjusted EPS for FY25 driven by specialty growth. Caution suggested as risks are skewed to downside, due to quarterly revenue miss and ongoing supply and demand issues for weight-loss drugs.
Mckesson Corporation MCK News Analytics from Thu, 01 Aug 2024 07:00:00 GMT to Sat, 08 Feb 2025 13:50:51 GMT -
Rating -3
- Innovation 6
- Information 7
- Rumor 3
